Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Raquel Bengió"'
Autor:
Maria Pagani, Alicia Enrico, Maria Josefina Freitas, Maria Elisa Riva, Miguel A. Pavlovsky, Luis Beligoy, Mariana Debus, Beatriz Moiraghi, Romina Mariano, Ricardo Khalil Tannuri, Dardo Riveros, Carolina Pavlovsky, Raquel Bengió, Mariel Ana Perez, Veronica Ventriglia, Georgina Bendek, Irene Larripa, Ana Ines Varela, Erica Franceschi, Francisca Rojas, Maria Victoria Osycka
Publikováno v:
Blood. 136:36-37
Background: Data on the safety and efficacy of copy drugs is usually unavailable. Imatinib mesylate is used to treat chronic myeloid leukemia (CML) patients in Argentina since 2002. During the last decade more than ten different imatinib copies are m
Autor:
Yesica Soledad Bestach, M. Rodríguez‐Zubieta, Alicia Enrico, C. Meyer, Raquel Bengió, Irene Larripa, C. D. De Brasi, M. Rivas, K. Scheps
Myelofibrosis (MF) is a Philadelphia-negative myeloproliferative neoplasm (MPN) characterized by clonal proliferation of hematopoietic stem cells, progressive bone marrow fibrosis, abnormal cytokine expression, anemia, splenomegaly, extramedullary he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0950ba3a76876e0a9b5afbd39a7a6e93
Wiley Online Library
Wiley Online Library
Autor:
Isabel Giere, Natalia Weich, Ariela Freya Fundia, Irene Larripa, Carolina Pavlovsky, Cristian Alberto Ferri, Beatriz Moiraghi, Raquel Bengió
Background: Chronic myeloid leukemia (CML) is associated to the BCR-ABL1 oncogene and can successfully be treated with tyrosine kinase inhibitors (TKIs). However, it remains still under investigation which molecular factors may influence CML risk or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::914cbf2494986405c36e96fb693bea8a
https://www.sciencedirect.com/science/article/pii/S1877782116300947
https://www.sciencedirect.com/science/article/pii/S1877782116300947
Autor:
Ariela Freya Fundia, Beatriz Moiraghi, Carolina Pavlovsky, Raquel Bengió, Cristian Alberto Ferri, Irene Larripa, Isabel Giere, Natalia Weich
BCR-ABL1 gene is a key molecular marker of chronic myeloid leukemia (CML), but it is still unclear which molecular factors may influence CML risk or lead to variable responses to tyrosine kinase inhibitors (TKIs). The aim of this study was to investi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7efbd2911884fea629c047cdb912907b
https://www.sciencedirect.com/science/article/pii/S1079979616300559
https://www.sciencedirect.com/science/article/pii/S1079979616300559
Autor:
Raquel Bengió, Cristian Alberto Ferri, Carolina Bárbara Belli, Gustavo Damián Icardi, Michele Bianchini, Irene Larripa
Publikováno v:
Leukemia & Lymphoma. 54:598-606
BCR–ABL1 point mutations are the most common cause of resistance in patients with chronic myeloid leukemia (CML) who fail or lose response to tyrosine kinase inhibitors. We have developed a rapid method to screen BCR–ABL1 mutations by high resolu
Autor:
María Gabriela Flores, Yesica Soledad Bestach, Carolina Bárbara Belli, Mario Giunta, Nora Watman, Yamila Sieza, Raquel Bengió, Marta Gelemur, Irene Larripa
Publikováno v:
Blood Cells, Molecules, and Diseases. 47:255-258
Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematological diseases characterized by refractory cytopenia(s). MDS patients show increased levels of tumor necrosis factor alpha (TNFα) which is a multifunctional proinflam
Autor:
Elsa Nucifora, Pedro Negri Aranguren, Francisco Sakamoto, Raquel Bengió, Carolina Bárbara Belli, Nora Watman, Maria Virginia Prates, María Gabriela Flores, Irene Larripa, Jorge Arbelbide
Publikováno v:
American Journal of Hematology. 86:540-545
Myelodysplastic syndromes (MDS) include a group of heterogeneous hematological disorders with a variable risk of leukemic evolution and short survival. Around 40-50% of patients show abnormal karyotypes that are mostly characterized by monosomies or
Autor:
Hector Murro, Miguel de Tezanos Pinto, Maria Elisa Riva, Veronica Ventriglia, Beatriz Moiraghi, Jorge Milone, Emilio Lanari, Raquel Bengió, Michele Bianchini, Eduardo Bullorsky, Irene Larripa
Publikováno v:
Leukemia & Lymphoma. 52:1720-1726
In imatinib-treated patients with chronic myeloid leukemia (CML), BCR-ABL mutations are the most common mechanism of resistance. Here we report the first multicenter Argentinean study investigating mutations in those patients with CML who fail or los
Autor:
Michele Bianchini, Patricia Gargallo, Irene Larripa, Mariana Selena Gonzalez, Beatriz Moiraghi, Raquel Bengió, Carlos Daniel de Brasi
Publikováno v:
Blood Cells, Molecules, and Diseases. 45:192-196
BCR-ABL fusion gene is implicated in the pathogenesis of chronic myeloid leukemia (CML), encoding the oncoprotein p210 BCR-ABL with anti-apoptotic activity. The inability to undergo apoptosis is an important mechanism of drug resistance and neoplasti
Autor:
Katia Canalejo, M. Rosso Saltó, V. Galán, Riera Ne, M. M. E. De Bracco, Raquel Bengió, M. Vermeulen, Gustavo L. Kantor, Marina Khoury, Mónica Aixalá
Publikováno v:
International Journal of Laboratory Hematology. 32:e96-e105
Introduction: Immune humoral neutropenia (Np) could be the consequence of anti-polymorphonuclear neutrophil (PMN) antibodies, circulating immune complexes (CIC) and/or antibodies against myeloid precursors. Granulocyte immunofluorescence test (GIFT)